Thus, both CRISPR/Cas9-based and pharmacological plectin inactivation in HCC potently inhibits metastatic load in the lungs, identifying plectin as a potential target against tumor dissemination in vivo. This evidence concerns the gene PLEC and hepatocellular carcinoma.